ClinicalTrials.gg
CompletedNCT05729373Updated Oct 10, 2025

A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

A Phase 2/3 interventional study of SEP-363856 and Placebo in Generalized Anxiety Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 83 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-10-10.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
434
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 265 studies in Generalized Anxiety Disorder with a site in United States — 38 open to participants now, 53 under way, 9 of them phase 3. Generalized Anxiety Disorder · United States.

Enrollment
34th of 234
434 · median 90
Started
2023
with 9 others
Phase 2/3
6 of 265
none open now
Registered
212th of 265
by date
Lead sponsor
6 of 265
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 265 studies in Generalized Anxiety Disorder with a site in United States, this one is the 34th largest by enrollment of the 234 interventional ones that give a count, is one of 10 that started in 2023, is one of 6 in phase 2/3, and was the 212th registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

38 of the 265 studies in Generalized Anxiety Disorder with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Generalized Anxiety Disorder with a site in United States, or all of them as a file.
02

Study summary

A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and approximately 15 additional centers for a separate Japan population. Participation in the study can be up to approximately 12 weeks.

Read the detailed description

This is a multicenter, randomized, double-blind, parallel-group, flexible dose, outpatient study evaluating the efficacy and safety of SEP-363856 flexibly dosed (50 - 75 mg/day) versus placebo over an 8-week Treatment Period in subjects with GAD. This study is projected to randomize approximately 434 subjects to 2 treatment groups (SEP-363856 [50 - 75 mg/day] or placebo) in a 1:1 ratio.

Approximately 30 additional subjects (N = 15 per treatment group) are projected to enroll in the Japan Cohort. Treatment assignment will be stratified by country. Study drug will be taken at approximately the same time each evening at bedtime .

03

Conditions studied

  • Generalized Anxiety Disorder

Keywords

  • Generalized Anxiety Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: (list is not all inclusive)

  • Male or female subject between 18 to 65 years of age.
  • Subject meets criteria for a diagnosis of Generalized Anxiety Disorder.
  • Subject must be willing and able to comply with the study procedures and visit schedule and must be able to understand and follow verbal and written instructions.

Exclusion Criteria: (list is not all inclusive)

  • Subject has DSM-5-based diagnosis of any disorder other than Generalized Anxiety Disorder that was the primary focus of treatment within 12 months before Screening.
  • Subjects who report an inadequate response to more than 3 antidepressant treatments
  • Subject is at significant risk of harming self or others based on Investigator's judgment.
  • Subject has any unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study.
  • Female subject who is pregnant, lactating, or plans to get pregnant during the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
434 participants (actual)

Study arms

  • Experimental
    SEP-363856

    dosed once daily tablet

    Drug: SEP-363856

  • Placebo comparator
    Placebo

    dosed once daily tablet

    Drug: Placebo

Interventions

  • once daily tablet

  • DrugPlacebo

    once daily tablet

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Endpoint

    The HAM-A scale consists of 14 items, each defined by a series of symptoms. Each item is rated on a 5-point (0-4) scale, with higher scores indicating greater severity.

    Time frame: Week 8

Secondary outcomes

  1. Change from Baseline in Clinical Global Impression-Severity (CGI-S) score at Endpoint

    The CGI-S is a clinician-rated assessment of the subject's current illness state on a 7-point scale, where a higher score is associated with greater illness severity.

    Time frame: Week 8

07

Study locations

83 sites
  • University of Alabama at Birmingham
    Huntsville, Alabama 35801, United States
  • IMA Clinical Research Phoenix
    Phoenix, Arizona 85012, United States
  • ProScience Research Group
    Culver City, California 90230, United States
  • Excell Research, Inc.
    Oceanside, California 92056, United States
  • Anderson Clinical Research
    Redlands, California 92374, United States
  • California Neuroscience Research, LLC
    Sherman, California 91403, United States
  • Schuster Medical Research Institute
    Sherman Oaks, California 91403, United States
  • Viking Pharmaceutical Trials Inc. dba Viking Clinical Research
    Temecula, California 92591, United States
  • CenExel Collaborative Neuroscience Research
    Torrance, California 90502, United States
  • Pacific Clinical Research Management Group
    Upland, California 91786, United States
  • CNS Healthcare
    Jacksonville, Florida 32256, United States
  • Combined Research Orlando
    Orlando, Florida 32803, United States
  • K2 Medical Research, LLC
    Tampa, Florida 33607, United States
  • CenExel iResearch Atlanta
    Atlanta, Georgia 30030, United States
  • Advanced Discovery Research LLC
    Atlanta, Georgia 30318, United States
  • NeuroTrials Research, Inc.
    Atlanta, Georgia 30328, United States
  • CenExel iResearch Savannah
    Savannah, Georgia 31405, United States
  • Uptown Research Institute, LLC
    Chicago, Illinois 60640, United States
  • American Medical Research, Inc.
    Warrenville, Illinois 60555, United States
  • Copley Clinical
    Boston, Massachusetts 02116, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Adams Clinical
    Watertown, Massachusetts 02472, United States
  • Midwest Research Group
    Saint Charles, Missouri 63304, United States
  • Center for Emotional Fitness Site
    Cherry Hill, New Jersey 08002, United States
  • CenExel Hassman Research Institute
    Marlton, New Jersey 08053, United States
  • Social Psychiatry Research Institute
    Brooklyn, New York 11235, United States
  • Neurobehavioral Research, Inc.
    Cedarhurst, New York 11516, United States
  • Bioscience Research, LLC
    Mount Kisco, New York 10016, United States
  • Berman Clinical
    New York, New York 10029, United States
  • Manhattan Behavioral Medicine
    New York, New York 10036, United States
  • The Medical Research Network, L.L.C
    New York, New York 10128, United States
  • Neuro-Behavioral Clinical Research, Inc.
    North Canton, Ohio 44720, United States
  • Sooner Clinical Research
    Oklahoma City, Oklahoma 73112, United States
  • Paradigm Research Professionals, LLP
    Oklahoma City, Oklahoma 73116, United States
  • Lehigh Center for Clinical Research, LLC
    Allentown, Pennsylvania 18104, United States
  • Psychiatry and Psychotherapy Partners Austin
    Austin, Texas 78737, United States
  • FutureSearch Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • Cedar Clinical Research, Inc.
    Draper, Utah 84020, United States
  • Medical Center Mentalcare OOD
    Sofia, Plovdiv 4004, Bulgaria
  • Medical Center Medconsult Pleven OOD
    Pleven, 5800, Bulgaria
  • MHC - Sofia, EOOD
    Sofia, 1000, Bulgaria
  • Medical Center "Sv.Naum"
    Sofia, 1113, Bulgaria
  • DCC "Sv. Vrach and Sv. Sv. Kuzma and Damyan", OOD
    Sofia, 1408, Bulgaria
  • Medical Center Hera EOOD
    Sofia, 1510, Bulgaria
  • Medical Center Intermedica, OOD
    Sofia, 1680, Bulgaria
  • DCC "Mladost M" - Varna, OOD Site #156
    Varna, 9020, Bulgaria
  • DCC "Mladost M" - Varna, OOD Site #157
    Varna, 9020, Bulgaria
  • Marienthali Kliinik
    Tallinn, 11315, Estonia
  • Tartu University Hospital
    Tartu, 50417, Estonia
  • Savon Psykiatripalvelu Oy
    Kuopio, Northern Savonia 70110, Finland
  • Aava Laakarikeskus - Aava Kamppi
    Helsinki, 00100, Finland
  • Mederon Oy
    Helsinki, 00100, Finland
  • Oulu Mentalcare Oy
    Oulu, 90100, Finland
  • Satakunnan Psykiatripalvelu
    Tampere, 33210, Finland
  • Uematsu Mental Clinic
    Chikugo-shi, Fukuoka 833-0041, Japan
  • Hiro Mental Clinic
    Fukuoka, Fukuoka 810-0004, Japan
  • Shinseikai Kaku Mental Clinic
    Fukuoka, Fukuoka 810-0022, Japan
  • Mental Clinic Sakurazaka
    Fukuoka, Fukuoka 810-0023, Japan
  • Kokura Mental Clinic
    Kitakyushu-shi, Fukuoka 802-0006, Japan
  • Hirota Clinic
    Kurume-shi, Fukuoka 830-0033, Japan
  • Hayakawa Clinic
    Kure-shi, Hiroshima 737-0111, Japan
  • Higashi-Sapporo Mental Clinic
    Sapporo, Hokkaido 003-0003, Japan
  • Shimode Mental Clinic
    Sapporo, Hokkaido 062-0922, Japan
  • Akari Clinic
    Naha, Okinawa 900-0004, Japan
  • Barclay Imuro Mental Clinic
    Urasoe-shi, Okinawa 901-2104, Japan
  • Senzoku Psychosomatic Medicine Clinic
    Meguro-ku, Tokyo-To 152-0012, Japan
  • Sangenjaya Nakamura Mental Clinic
    Setagaya-ku, Tokyo-To 154-0004, Japan
  • Sangenjaya Neurology- Psychosomatic Clinic
    Setagaya-ku, Tokyo-To 154-0004, Japan
  • MENTUM, s.r.o.
    Bratislava, 82007, Slovakia
  • Epamed sro
    Košice, 040 01, Slovakia
  • PsychoLine s.r.o.
    Rimavská Sobota, 97901, Slovakia
  • Crystal Comfort s.r.o.
    Vranov nad Topľou, 9301, Slovakia
  • BONA MEDIC, s.r.o.
    Zlaté Moravce, 95301, Slovakia
  • Hospital Universitario Fundacion Alcorcon
    Alcorcón, Madrid 28922, Spain
  • Hospital Valle del Nalon
    Langreo, Principality of Asturias 33920, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 8025, Spain
  • Institucion Hospitalaria Hestia Palau
    Barcelona, 8025, Spain
  • Hospital Universitario Infanta Leonor
    Madrid, 28031, Spain
  • Hospital de Antequera
    Málaga, 29200, Spain
  • Sahlgrenska Universitetssjukhuset - Östra sjukhuset
    Gothenburg, 416 50, Sweden
  • ProbarE- Lund
    Lund, 22222, Sweden
  • PharmaSite AB Malmö
    Malmö, 21152, Sweden
  • ProbarE- Stockholm
    Stockholm, 113 29, Sweden
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Sep 2025, 30 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2023
First posted
Feb 15, 2023
StartActual
Mar 8, 2023
Primary completionActual
Sep 26, 2025
CompletionActual
Sep 26, 2025
Last update
Oct 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05729373
Responsible party
Sponsor
First posted
Feb 15, 2023
Start date
Mar 8, 2023
Primary completion
Sep 26, 2025
Completion
Sep 26, 2025
Last update
Oct 10, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SEP-363856

Start the discussion